Table GPS-5. Last month prevalence of drug use among all adults (aged 15 to 64 years) in nationwide surveys among the general population

Country Geographical area		Year	Reference	Age range all adults	Sample size all adults	Cannabis (%)	Cocaine (%) (1)	Amphetamines (%) (2)	Ecstasy (%) (3)	LSD (%)
Belgium
Vlaanderen (Brussels excluded)		1994	(1)	18-65	2259
French Community		1996–97	(2)	18-49	978	1.3
French Community		1998–99	(3)	18-49	1006	3.4
French Community		2000	(4)	18-49	693	3.8
National		2001	(5)	15-64	7347	2.7		0.3
National		2004	(6)	15-64		3
Bulgaria
National		2005	(1)	18-60	1036	0.8	0.2	0.2	0.5	0.2
Czech Republic
National		2002	(1)	18-64	2526
National		2004	(2)	18-64	3526	4.8	0	0.2	1.1	0.1
Denmark
National		1990	(1)	>=16	2000
National		1994	(2)
National		2000	(3)	16-64	11825	2.8	0.3	0.3	0.2	0.1
National		2005	(4)	16-64	13310	2.6	0.3	0.3	0.1	0
Germany
East Germany		1990	(1)
Western Germany		1990	(2)
Old and new Länder		1995	(3)	18-59	7833	2.8	0.4	0.3	0.5
Old and new Länder		1997	(4)	18-59	8019	2.8	0.3	0.2	0.3
National		2000	(5)	18-59	8139	3.3	0.2	0.2	0.3	0.1
National		2003	(6)	18-59	8061	3.4	0.4	0.4	0.2	0.1
National		2006	(7)	18-64	7912	2.2	0.2	0.3	0.2	0
Estonia
National		1998	(1)	18-64	2317	2
National		2003	(2)			1.4	0	0.3	0.4	0
Ireland
National		1998	(1)	18-64	826
National		1998	(2)	18-64		5.1
National		2000	(3)	18-64	907
National		2002–03	(4)	15-64	4918	2.6	0.3	0.2	0.3	0
National		2006–07	(5)	15-64	4967	2.6	0.5	0.1	0.3	0
Greece
Athens		1993	(1)	12-64	2103
National (except Aegean and Ionian Islands)		1998	(2)	15-64	3398	2.3	0.2	0	0
National (except Aegean and Ionian Islands)		2004	(3)	15-64	4351	0.9	0	0	0	0
Spain
National		1995	(1)	15-64	8888
National		1997	(2)	15-65	12515	4	0.8	0.3	0.2
National		1999	(3)	15-64	12234	4.5	0.8	0.2	0.5
National		2001	(4)	15-64	14113	6.8	1.4	0.6	0.8
National		2003	(5)	15-64	12033	7.6	1.1	0.2	0.4
National		2005–06	(6)	15-64	27934	8.7	1.6	0.4	0.6
France
National		1992	(1)	15-64	2099
Metropolitan France		1995	(2)	18-75	1787
National		1999	(3)	18-69	1742
National		2000	(4)	15-64	11317	4.3	0.1	0.1	0.1	0.1
Metropolitan France		2002	(5)	15-64	1744
National		2005	(6)	15-64	25879	4.8	0.2	0.1	0.1	0
Italy
National		2001	(1)	15-44	6032	4.4	0.7	0	0.2	0
National		2003	(2)	15-54	11869	4.6	0.6	0.1	0.1	0.1
National		2005	(3)	15-64	27995	5.8	0.8	0.2	0.2	0.2
Cyprus
National		2006	(1)	15-64	3504	1.4	0.4	0.3	0.6	0.3
Latvia
National		2003	(1)	15-64	4534	1.8	0.1	0.5	0.3	0.3
Lithuania
National		2004	(1)	15-64	4207	0.7	0.1	0.1	0.2	0
Luxembourg
National		1998	(1)	15-64		4	0.2		0	0
Hungary
National		2001	(1)	18-65	2359	1.1	0.1	0.3	0.3	0.1
National		2003	(2)	18-54		1.4	0.2	0.4	0.4	0.2
Malta
National		2001	(1)	18-64		0.5	0.1	0	0.2	0
Netherlands
National		1997–98	(1)	15-64	17590	3	0.3	0.1	0.3
National		2001	(2)	15-64	2312	3.4	0.1	0	0.3	0
National		2005	(3)	15-64	4516	3.3	0.3	0.2	0.4	0
Austria
National		2004	(1)	15-64	3980	3.8	0.4	0.4	0.4	0.1
Poland
National		2002	(1)	16-64		1.3	0.1	0.2	0.2	0
National		2006	(2)	15-64	2859	0.9	0.1	0.2	0.1	0
Portugal
National		2001	(1)	15-64	14186	2.4	0.1	0.1	0.2	0
National		2007	(2)	15-64	12202	2.4	0.3	0.1	0.2	0.1
Romania
National		2004	(1)	15-64
Slovakia
National		1996	(1)	15-64		1.7	0.2	0
National		1998	(2)	15-64		1.4	0.1	0	0.1
National		2000	(3)	15-64	1254	2.4	0.1	0	0.2
National		2002	(4)	18-64	1269	2.7	0	0.1	0.1
National		2004	(5)	15-64	1315	1.7	0.1	0	0.4
National		2006	(6)	15-64	1305	2	0.2	0.2	0.5
Finland
National		1992	(1)	18-74	3457
National		1996	(2)	16-74	3009
National		1998	(3)	15-69	2568
National		2000	(4)	15-64	1677	0.7	0.1	0.1	0.1	0.1
National		2002	(5)	15-64	2377	1.1	0	0.2	0.1	0
National		2004	(6)	15-64	2352	1.6	0	0.2	0.2	0.1
National		2006	(7)	15-64	2802	1.6	0.1	0.2	0.1	0
Sweden
National		1994	(1)	16-64	806
National		1996	(2)	16-64	1136
National		1998	(3)	16-64	1359	0.2	0	0.1	0
National		2000	(4)	16-64	1750	0.2	0	0.1	0	0
National		2004	(5)	18-64	9514	0.8
National		2005	(6)	16-64	30538	0.8
National		2006	(7)	16-64	41701	0.6
United Kingdom
England and Wales		1994	(1)	16-59	9645	4.9	0.2	1	0.4	0.5
England and Wales		1996	(2)	16-59	10935	5.5	0.3	1.6	0.7	0.3
England and Wales		1998	(3)	16-59	9984	6.1	0.5	1.4	0.5	0.1
England and Wales		2000	(4)	16-59	13018	6.4	0.8	0.9	0.9	0.1
England and Wales		2001–02	(5)	16-59	20165	6.6	0.9	0.7	1.1	0.1
England and Wales		2002–03	(6)	16-59	23586	6.7	0.9	0.6	0.9	0.1
England and Wales		2003–04	(7)	16-59	24422	6.5	1.1	0.6	0.9	0.1
England and Wales		2004–05	(8)	16-59	28509	5.6	0.9	0.5	0.7	0
England and Wales		2005–06	(9)	16-59	29748	5.2	1.2	0.6	0.7	0.1
England and Wales		2006–07	(10)	16-59	31054	4.8	1.3	0.5	0.8	0.1
Northern Ireland		2002–03	(11)	15-64	3516	2.9	0.1	0.2	0.5	0
Northern Ireland		2005	(12)	16-59		3.4	0.2	0.4	0.4	0
Scotland		2003	(13)	16-64	3506	4.2	0.4	0.3	0.6	0
Scotland		2004	(14)	16-64	3293	3	0.4	0.4	0.3	0.1
Scotland		2006	(15)	16-59	3157	6.8	1.8	0.9	1.6	0.2
United Kingdom		2004	(16)			6.2	1	0.5	0.9	0.1
Norway
National		1999	(1)	15-64	1803	2.4	0	0.4	0.2
National		2004	(2)	15-64	2669	2.2	0.3	0.2	0.1	0

Notes:

 (1) Cocaine, any form. 

 (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy, for Denmark National 1994: hard drugs. 

 (3) For Spain: ecstasy and other designer drugs. 

 (4) In the Netherlands, the figures for 2001 have been recomputed using only the interviews conducted with the CAPI method (Computer Assisted Personal Interview) and excluding other methods of data collection (mail, telephone, etc.) to ensure comparability with 1997 and 2005. For 2005, only respondents with information collected through the CAPI method were included (this note applies to all tables and graphics regarding population surveys for the Netherlands 2001 and 2005). 

 This table aims to present an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as reference point for the 1993 survey.  

 In surveys with small sample sizes results should be interpreted with caution. 

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15–64, young adults: 15–34). In countries where age ranges are more restrictive, prevalence estimates tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

 For methods and definitions on population surveys in general, see General population surveys of drug use – <a href="https://www.emcdda.europa.eu/stats08/gps/methods">methods and definitions</a>. 

 For methods of each survey presented in this table, see <a href="https://www.emcdda.europa.eu/stats08/gpstab1b">Table GPS-1 part (ii)</a>.  

 See also 'General notes for interpreting data' on the <a href="https://www.emcdda.europa.eu/stats08/help">Explanatory notes and help page</a>. 

Sources:

 See <a href="https://www.emcdda.europa.eu/stats08/gpstab0">Table GPS-0</a>. 

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)